RecruitingNCT05046613

Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

A Prospective, Registry-based, Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant: The Migraine Observational Nurtec Pregnancy Registry (MONITOR)

Sponsor

Pfizer

Enrollment

780 participants

Start Date

Sep 23, 2021

Study Type

OBSERVATIONAL

Conditions

Migraine

Summary

The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.

Eligibility

Sex: FEMALEMin Age: 0 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Not taking Rimegepant and Rimegepant for people with migraine. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 0 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.